KEQU

Kewaunee ScientificB

Nasdaq / Health Care Equipment & Services

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$42.00

+3.5% vs current

Most likely

Base case

50%

Probability

Target price

$35.00

-13.7% vs current

B-

Bear case

25%

Probability

Target price

$27.00

-33.4% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Primary-source evidence supports a cautious, neutral view: KEQU is still profitable and internationally resilient, but the latest quarter showed enough backlog and domestic-volume softness that the thesis remains a monitoring story until the FY26 year-end release resolves whether execution merely slipped in timing or demand softened more materially.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-25eventFY26 Q4 and year-end release should clarify whether Q3 was timing noise or demand slippageHigh impact

Kewaunee's fiscal year ends April 30, and prior full-year results were released on June 25, 2025; the next annual results should therefore be the key catalyst to confirm backlog conversion, margin recovery, and cash generation. Given the weaker Q3 backlog and domestic mix, the setup is more of a verification event than a clear upside trigger [#8-K-2026-03-11] [#10-K-2025-07-02].

2026-06-25catalystQ3 backlog reset and domestic volume pressure need stabilizationMedium impact

Q3 FY26 sales rose 3.3% to $69.4M, but backlog fell to $183.2M from $214.6M at April 30, 2025 and domestic profitability was hurt by lower manufacturing volumes in laboratory construction, while international profitability improved on stronger India billings [#8-K-2026-03-11]. Near-term sentiment likely hinges on whether domestic execution stabilizes before the next print.

2026-09-10catalystNu Aire integration can still help mix, but benefits remain partially offset by cost and balance-sheet dragHigh impact

Management continues to highlight Nu Aire as a complementary product platform, but Q3 still carried integration-related fees and year-to-date interest expense rose to $3.2M from $2.1M. If cross-sell and product mix benefits outweigh integration and financing drag, medium-term earnings quality can improve; if not, KEQU stays a lumpy project-driven story [#8-K-2026-03-11] [#10-K-2025-07-02].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology